Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
NCT07229638Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2026
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-9839 in solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
SHR-9839
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07229638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229638.